Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMANTADINE HYDROCHLORIDE vs ACYCLOVIR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Amantadine hydrochloride is an antiviral and antiparkinsonian agent. Its antiviral mechanism involves inhibition of the M2 ion channel of influenza A virus, preventing viral uncoating and replication. In Parkinson's disease, it increases dopamine release and inhibits dopamine reuptake, and also acts as an NMDA glutamate receptor antagonist, reducing excitotoxicity.
Acyclovir is a synthetic nucleoside analog that inhibits viral DNA replication. It is phosphorylated to acyclovir monophosphate by viral thymidine kinase, then converted to acyclovir triphosphate by cellular kinases. Acyclovir triphosphate competes with deoxyguanosine triphosphate for viral DNA polymerase, incorporating into viral DNA and causing chain termination.
Prophylaxis and treatment of influenza A virus infection,Treatment of Parkinson's disease and drug-induced extrapyramidal symptoms
Herpes simplex virus (HSV) infections: genital herpes, herpes labialis, herpes simplex encephalitis, neonatal herpes,Varicella-zoster virus (VZV) infections: chickenpox, herpes zoster (shingles),Mucocutaneous HSV infections in immunocompromised patients,Prophylaxis of HSV and VZV infections in immunocompromised patients
For parkinsonism/drug-induced extrapyramidal symptoms: initial 100 mg twice daily; may increase to 300-400 mg/day in divided doses if needed. For influenza A treatment/prophylaxis in adults: 200 mg once daily or 100 mg twice daily; initiate prophylaxis as early as possible and continue for at least 10 days post-exposure.
400 mg orally twice daily for herpes zoster; 200 mg orally 5 times daily for genital herpes; 5-10 mg/kg intravenously every 8 hours for severe infections.
Terminal elimination half-life: 10-14 hours in young adults; up to 34 hours in elderly (due to age-related decline in renal function); prolonged in renal impairment (up to 7 days in anuria).
Terminal elimination half-life is 2.5–3.3 hours in adults with normal renal function; increases to 19.5 hours in anuria.
Amantadine is primarily excreted unchanged in urine via glomerular filtration and tubular secretion. It undergoes minimal hepatic metabolism, with no major cytochrome P450 involvement.
Acyclovir is partially metabolized by alcohol and aldehyde dehydrogenase. The major metabolite is 9-carboxymethoxymethylguanine (CMMG), which is inactive. Hepatic metabolism is minimal, and the drug is predominantly excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal: 90% unchanged drug via glomerular filtration and tubular secretion; minor fecal (<5%) and biliary elimination.
Renal excretion of unchanged drug via glomerular filtration and tubular secretion accounts for 62-90% of elimination. Fecal elimination is <2%.
Approximately 67% bound to plasma proteins (mainly albumin).
9–33% bound to plasma proteins (albumin).
3-10 L/kg, indicating extensive tissue distribution (e.g., brain, lungs, erythrocytes).
Vd: 0.5–1.5 L/kg. Distributes widely; crosses blood-brain barrier achieving 50% of plasma CSF concentration.
Oral bioavailability: 86-90% after immediate-release formulation; steady-state achieved within 4-7 days.
Oral: 15–30% (dose-dependent). Topical: Minimal systemic absorption (<5%).
Cr Cl 30-50 m L/min: 200 mg on day 1, then 100 mg once daily. Cr Cl 15-29 m L/min: 200 mg on day 1, then 100 mg every other day. Cr Cl <15 m L/min or on hemodialysis: 200 mg every 7 days. Adjust based on clinical response and tolerability.
Cr Cl >25 m L/min: no adjustment; Cr Cl 10-25 m L/min: standard dose every 12 hours; Cr Cl <10 m L/min: standard dose every 24 hours.
No specific dosage adjustment required in hepatic impairment, but use with caution due to potential central nervous system effects.
No dose adjustment required for hepatic impairment; no Child-Pugh based modifications established.
Influenza A treatment/prophylaxis: children 1-9 years: 4.4-8.8 mg/kg/day (max 150 mg/day) in 1-2 divided doses; 9-12 years: 100 mg twice daily; ≥12 years: adult dosing. Not routinely recommended due to widespread resistance.
Neonates: 10-20 mg/kg intravenously every 8 hours; Children: 250-600 mg/m² orally 3-5 times daily or 5-10 mg/kg intravenously every 8 hours.
Initiate at 100 mg once daily or lower, considering age-related decline in renal function; titrate slowly with careful monitoring for adverse CNS effects.
Adjust based on renal function; start at low end of dosing range; monitor for neurotoxicity.
None
None. Acyclovir does not have a black box warning.
Risk of suicidality, especially in patients with a history of psychiatric disorders,May exacerbate seizure disorder; use with caution in epilepsy,Can cause orthostatic hypotension, dizziness, and blurred vision, impairing ability to drive or operate machinery,Neuroleptic malignant syndrome (NMS) has been reported with dose reduction or discontinuation,Renal function impairment requires dose adjustment; accumulation can cause toxicity,Elderly patients are more susceptible to CNS effects
Renal impairment: Dose adjustment required for Cr Cl < 50 m L/min; risk of acute renal failure due to crystallization in renal tubules, especially with rapid IV infusion or dehydration,Neurologic toxicity: Elderly patients or those with renal impairment may develop CNS effects (agitation, hallucinations, seizures); use with caution,Hematologic: Rare reports of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) in immunocompromised patients,IV administration: Avoid rapid infusion, ensure adequate hydration to prevent renal damage
Hypersensitivity to amantadine or any component of the formulation,Severe uncontrolled psychiatric disorder (relative)
Hypersensitivity to acyclovir or valacyclovir,Lactation: Caution advised; excreted in breast milk
Avoid alcohol and caffeine; alcohol may increase CNS depression, caffeine may exacerbate insomnia and nervousness. No specific food restrictions.
No significant food interactions. High-fat meals may reduce absorption but not clinically significant. Avoid excessive alcohol as it may worsen side effects (e.g., dizziness).
First trimester: Human data limited; animal studies (rat, rabbit) at doses 2-3 times human therapeutic dose showed increased fetal malformations (cardiovascular, skeletal). Second and third trimesters: No controlled data; case reports of preeclampsia, premature labor, and fetal distress with use near term. FDA Pregnancy Category C.
Acyclovir is generally considered low risk during pregnancy. Data from the Acyclovir Pregnancy Registry and postmarketing studies do not show an increased risk of major birth defects compared to the general population. However, high-dose IV acyclovir in first trimester for severe infections carries theoretical risk; use only if clearly needed. No known specific fetal risks by trimester beyond those of the underlying infection.
Amantadine is excreted into breast milk; milk-to-plasma ratio (M/P) approximately 0.7-1.0 (based on single case, M/P 1.0 at 200 mg/day). Infant serum concentrations up to 6% of maternal therapeutic levels reported. Potential for anticholinergic effects and extrapyramidal symptoms in nursing infant. AAP recommends caution; weight benefits vs. risks.
Acyclovir is excreted into breast milk with a milk-to-plasma ratio (M/P) of approximately 0.6 to 4.1. An exclusively breastfed infant would receive 0.1-1% of maternal dose (or 0.3-0.7 mg/kg/day based on typical maternal 200 mg oral dose), which is below neonatal therapeutic doses. American Academy of Pediatrics considers acyclovir compatible with breastfeeding. Monitor infant for rash or gastrointestinal disturbance.
Pregnancy increases renal clearance (by 20-50% in second/third trimester) due to increased glomerular filtration rate. For Parkinson's disease or influenza A, consider starting at lower dose (100 mg daily) and titrate upward as needed, monitoring for efficacy and CNS side effects. No standard dose adjustment guidelines; individualize based on therapeutic response and tolerance.
Pregnancy does not significantly alter acyclovir pharmacokinetics; no dose adjustment needed for oral or IV acyclovir. Standard dosing regimens for HSV (e.g., 200-400 mg PO TID for genital herpes or 5-10 mg/kg IV q8h for severe infection) are used. In third trimester, increased renal clearance may require slightly higher doses for VZV (typically 800 mg PO 5 times/day), but no formal recommendations for dose increase. Always adjust for renal impairment separately.
For Parkinson's disease, start at 100 mg twice daily; increase gradually to 100 mg TID or QID if needed. In elderly or renal impairment, reduce dose. Avoid abrupt discontinuation to prevent neuroleptic malignant syndrome. Monitor for orthostatic hypotension, livedo reticularis, and peripheral edema. Can worsen psychosis in patients with dementia. For influenza A, start within 48 hours of symptoms; not a substitute for vaccination. Use with caution in patients with seizure disorders or heart failure.
Acyclovir requires adequate hydration to prevent crystalluria and nephrotoxicity; ensure urine output >500 m L/q8h. For IV acyclovir, infuse over at least 1 hour to avoid renal damage. Dose adjustment required in renal impairment (Cr Cl <50 m L/min). Early initiation (within 72 hours of rash) improves outcomes in herpes zoster. Oral acyclovir has low bioavailability (15-30%); valacyclovir is a prodrug with better absorption.
Take exactly as prescribed; do not stop suddenly without consulting your doctor.,May cause dizziness or blurred vision; avoid driving until you know how this medicine affects you.,Avoid alcohol as it may increase side effects like dizziness.,Notify your doctor if you experience swelling in your legs or ankles, a lacy purple skin rash, or confusion.,If you miss a dose, take it as soon as you remember unless it is close to your next dose; do not double up.,Wear sunscreen and protective clothing; amantadine may make your skin more sensitive to sunlight.,Do not take this medicine for influenza unless directed by a doctor; it is not a substitute for the flu vaccine.
Take acyclovir exactly as prescribed, even if symptoms improve.,Drink plenty of water during treatment to prevent kidney problems.,Start medication at the first sign of outbreak for best results.,Do not share your medication with others.,Avoid sexual contact when lesions are present to prevent transmission.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Concurrent administration of naloxegol, a peripherally-acting mu-opioid receptor antagonist, may increase the serum concentration of amantadine, a weak NMDA receptor antagonist and antiviral agent. This interaction is proposed to occur via competitive inhibition of renal tubular secretion mediated by organic cation transporters (OCTs) present in the proximal tubule, leading to reduced amantadine clearance. Clinically, elevated amantadine levels can precipitate dose-related adverse effects including confusion, hallucinations, orthostatic hypotension, and peripheral edema, particularly in elderly patients or those with pre-existing renal impairment."
"Anagrelide is a phosphodiesterase 3 (PDE3) inhibitor with dose-dependent QT interval prolongation risk due to inhibition of the hERG potassium channel. Amantadine, a dopamine agonist and antiviral agent, also has mild QTc-prolonging properties, possibly through direct myocardial ion channel effects. Concomitant use may result in additive QT interval prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias."
"Amantadine, an antiviral and antiparkinsonian agent with weak NMDA receptor antagonist properties, may reduce the antipsychotic efficacy of mesoridazine, a phenothiazine antipsychotic. This interaction likely occurs via pharmacodynamic opposition, where amantadine's dopaminergic activity counteracts mesoridazine's dopamine receptor blockade in the central nervous system. Clinically, this can lead to worsening of psychotic symptoms or reduced therapeutic response to mesoridazine."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMANTADINE HYDROCHLORIDE vs ACYCLOVIR, answered by our medical review team.
AMANTADINE HYDROCHLORIDE is a Antiviral / Antiparkinsonian that works by Amantadine hydrochloride is an antiviral and antiparkinsonian agent. Its antiviral mechanism involves inhibition of the M2 ion channel of influenza A virus, preventing viral uncoating and replication. In Parkinson's disease, it increases dopamine release and inhibits dopamine reuptake, and also acts as an NMDA glutamate receptor antagonist, reducing excitotoxicity.. ACYCLOVIR is a Antiviral that works by Acyclovir is a synthetic nucleoside analog that inhibits viral DNA replication. It is phosphorylated to acyclovir monophosphate by viral thymidine kinase, then converted to acyclovir triphosphate by cellular kinases. Acyclovir triphosphate competes with deoxyguanosine triphosphate for viral DNA polymerase, incorporating into viral DNA and causing chain termination.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMANTADINE HYDROCHLORIDE and ACYCLOVIR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMANTADINE HYDROCHLORIDE is: For parkinsonism/drug-induced extrapyramidal symptoms: initial 100 mg twice daily; may increase to 300-400 mg/day in divided doses if needed. For influenza A treatment/prophylaxis in adults: 200 mg once daily or 100 mg twice daily; initiate prophylaxis as early as possible and continue for at least 10 days post-exposure.. The standard adult dose of ACYCLOVIR is: 400 mg orally twice daily for herpes zoster; 200 mg orally 5 times daily for genital herpes; 5-10 mg/kg intravenously every 8 hours for severe infections.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMANTADINE HYDROCHLORIDE and ACYCLOVIR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMANTADINE HYDROCHLORIDE is classified as Category C. First trimester: Human data limited; animal studies (rat, rabbit) at doses 2-3 times human therapeutic dose showed increased fetal malformations (cardiovascular, skeletal). Second . ACYCLOVIR is classified as Category A/B. Acyclovir is generally considered low risk during pregnancy. Data from the Acyclovir Pregnancy Registry and postmarketing studies do not show an increased risk of major birth defec. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.